1-20 of 38
Keywords: Doxorubicin
Close
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2018) 94 (5): 324–328.
Published Online: 13 March 2018
... evaluate the activity of an association of 1G3-Cu with 5 cytotoxic agents used in chemotherapy having different modes of action. Data show no additive effect with camptothecin and cisplatin, additivity with paclitaxel and MG132, and synergy with doxorubicin. Results suggest that the multivalent Cu...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2012) 83 (6): 305–320.
Published Online: 05 September 2012
... chemotherapeutic resistance. This study investigates the molecular responses of ER+ breast cancer cell lines to the chemotherapeutic agent, doxorubicin, in the presence or absence of estrogen. Methods: ER+ MCF-7 and T47-D cells were cultured in hormone-starved or estrogen-containing media with or without...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2012) 83 (2): 75–82.
Published Online: 29 June 2012
... XIAP expression in U87MG glioblastoma using stable shRNA, and cells were treated with taxol, BCNU, temozolomide, cisplatin, etoposide, resveratrol (Rsv), vincristine and doxorubicin. We analyzed cell viability, cell cycle, apoptosis and senescence. Results: XIAP KD cells were more sensitive...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1996) 53 (6): 461–470.
Published Online: 30 June 2009
... of these methods in evaluating cardiotoxicity, and an algorithm to optimally monitor antitumor therapy-induced cardiomyopathy are discussed. 30 6 2009 Cardiotoxicity Ejection fraction, left ventricular Doxorubicin Peak filling rate © 1996 S. Karger AG, Basel 1996 Copyright / Drug Dosage...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1997) 54 (2): 153–157.
Published Online: 30 June 2009
...Tsukasa Hotta; Hiroshi Tanimura; Hiroki Yamaue; Makoto Iwahashi; Masaji Tani; Takuya Tsunoda; Mikiko Tamai; Kohei Noguchi; Shizuma Mizobata; Kazuo Arii; Hiroshi Terasawa Resistance to doxorubicin (DOX) is mainly due to the effect of P-glycoprotein encoded by the multidrug resistance (MDR) gene...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1995) 52 (1): 60–65.
Published Online: 30 June 2009
... to either methotrexate (10 -6 -10 -4 M ), doxorubicin (10 -7 -10 -5 M ) or mitoxantrone (10 -7 -10 -5 M). In HPMC exposed to doxorubicin (10 -6 M ) the intracellular transport of potassium, as assessed with 86 Rb as its analogue, was not affected. Methotrexate (10 -5 M ) diminished Na, K-ATPase activity...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1994) 51 (1): 102–107.
Published Online: 30 June 2009
...Nissim Haim; Medy Tsalik; Eliezer Robinson The results of two schedules of the combination of etoposide, doxorubicin, and cisplatin (EAP) in gastric cancer are reported. EAP-1 was administered as originally reported and consisted of i.v. doxorubicin (adriamycin) 20 mg/m 2 on days 1 and 7, i.v...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1994) 51 (Suppl. 1): 29–32.
Published Online: 30 June 2009
... neutropenia, may necessitate dose reductions and may ultimately limit its use as a long-term treatment. Sequential or simultaneous administration of Taxol and doxorubicin may enhance response rates. There appears to be no complete cross-resistance between the two drugs. Current trials are exploring the best...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1991) 48 (4): 327–333.
Published Online: 26 June 2009
..., adenosine and guanosine triphosphate levels, and 14 C-amino acid incorporation, of rat hearts treated with doxorubicin and some of its derivatives, recent products of pharmacological research aimed at selecting less toxic antiblastic agents. In rats treated in vivo, we further examined the ultrastructural...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1990) 47 (2): 105–108.
Published Online: 26 June 2009
...Giuseppe Giaccone; Michela Donadio; Gianmaria Bonardi; Franco Testore; Alessandro Calciati Nineteen evaluable patients with advanced breast cancer were treated with a combination of doxorubicin and etoposide. Patients had measurable disease, received only mild pretreatment and most had good general...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1990) 47 (5): 427–432.
Published Online: 26 June 2009
...Andrea Martoni; Edera Piana; Monica Guaraldi; Giuseppina Cilenti; Antonio Farris; Ferruccio Saccani; Giorgio Becchi; Franco Pannuti The aim of the present study is to confirm the antitumor activity of orally administered idarubicin (IDA) in patients with advanced breast cancer. Doxorubicin (ADRIA...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1991) 48 (1): 7–12.
Published Online: 26 June 2009
..., instructions or products referred to in the content or advertisements. Advanced ovarian cancer Ovarian cancer, FIGO stages III and IV Chemotherapy Cyclophosphamide Doxorubicin Adriamycin Cisplatin Laparotomy, second-look Second-effort surgery Oncology 1991 ;48:7 12 « 1991 S. Karger AG. Basel...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1988) 45 (3): 242–246.
Published Online: 25 June 2009
... derivatives or coenzyme Q 10 could provide protection against doxorubicin-related cardiac damage. Rat heart slices were incubated for 60 min in a Warburg apparatus at 38°C with 4 mM L-carnitine or 1 m M propionyl carnitine or 15 μM coenzyme Q 10 to which 25 μM doxorubicin was added. Cellular oxygen uptake...